Navigation Links
New Data Demonstrate Longer-Term Safety Profile of Esbriet®
Date:9/26/2011

AMSTERDAM, Sept. 26, 2011 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today reported that new data(1) was presented at the European Respiratory Society (ERS) Annual Congress supporting the longer-term safety and tolerability of Esbriet® (pirfenidone) in patients with idiopathic pulmonary fibrosis (IPF), a devastating lung disease.  Approximately 30,000-35,000 new IPF patients are diagnosed in Europe each year, with an estimated median survival of only two to five years. The announcement follows the recent marketing authorization of Esbriet in Europe and its first launch in Germany on 15 September.

Professor Ulrich Costabel, from the Department of Pneumology/Allergy at the Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany who presented the data, said: "These new data from the RECAP study show that the safety profile of pirfenidone remains consistent, even when pirfenidone treatment continued beyond three years, thereby adding to the growing body of evidence that supports the treatment of IPF with pirfenidone. This news should be welcomed by European clinicians who will soon have the opportunity to treat their mild to moderate IPF patients with this new medicine."

The RECAP extension study data, presented on 25 September at ERS, highlighted the positive longer-term safety and tolerability of Esbriet in patients with IPF. RECAP is an open-label extension study for patients who participated in the Phase 3 program for Esbriet, known as CAPACITY.  The CAPACITY program (studies 004 and 006) was designed to evaluate the treatment effect of Esbriet in IPF patients. In the CAPACITY studies, 779 patients were randomized to treatment with Esbriet or placebo and 626 patients completed the study. Of these, 603 (96 percent) were enrolled in RECAP.  

"IPF is a devastating condition with no proven management options other than
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis
2. Inovio Pharmaceuticals Completes PENNVAX™-B HIV Vaccine Phase I Study, Demonstrates Best-in-Class T-Cell Immune Responses
3. Germgard Lighting Demonstrates the Worlds Most Effective Hand Sterilizer to Protect Against Contagion
4. NIH-Funded Study Demonstrates That Patients Receiving New CPR Devices (ResQPOD® and ResQPump™) and Cooling Have Improved Long-Term Brain Function Following Cardiac Arrest
5. New Digital Linear Accelerator Control System Demonstrates Treatment Time Savings of Up to 30 Percent
6. Obese Patients Treated With QNEXA Demonstrated Significant Improvement in Quality of Life
7. Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I
8. New Research Demonstrates High Prevalence of Sexually Transmitted Disease Trichomonas Vaginalis and Potential of New Molecular Test to Improve Detection
9. Topaz Pharmaceuticals Ivermectin Cream In Vitro Data Demonstrates Activity Against Head Lice Eggs
10. Halozymes Ultrafast Insulin Demonstrates Reduced Variability of Insulin Absorption for Type 1 Diabetes Patients Using Insulin Pumps
11. CureFAKtor Pharmaceuticals Demonstrates that Novel Focal Adhesion Kinase (FAK) Inhibitors Decrease Pancreatic Cancer Tumor Blood Flow and Reduce Blood Vessel Density
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015 RadiologyAuction will have their first ... and product demonstrations at the end of the auction ... as Kodak and Fuji Cr,s, Agfa and Sony, printers ... first event. Various imaging equipment will be available at ... After years of buying and selling imaging equipment, ...
(Date:5/4/2015)... 2015 Rogne Bioscience, a privately-held biotechnology company ... preclinical and mechanism of action data will be presented ... Dermatology (SID) Annual Meeting being held May 6-9, 2015 ... . Logo - http://photos.prnewswire.com/prnh/20150501/213318LOGO ... a novel, low MW (<1700 daltons) peptide as a ...
(Date:5/4/2015)... -- Bayer HealthCare (Bayer) has entered into an exclusive ... ) on ISIS-FXI Rx, an antisense investigational drug ... the agreement Bayer will further develop and commercialize ISIS-FXI ... As part of the clinical development program, Bayer plans ... in an appropriate patient community. "Bayer is ...
Breaking Medicine Technology:RadiologyAuction Announces Event Starting On May 5th 2Rogne Bioscience to Present Data from Topical Biologic Psoriasis Program at Upcoming SID Annual Meeting 2015 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3
... SINGAPORE , UPPSALA, Sweden and CANTON, Mass. , ... that the US Food and Drug Administration (FDA) has given the ... Mesh, for use in reinforcement of soft tissues where weakness exists. ... synthetic matrix, knitted from two different resorbable fibers that degrade at ...
... SAN FRANCISCO, Calif. , Feb. 5 Poniard Pharmaceuticals, Inc. ... today announced that Ronald Martell , chief executive officer, will provide ... on Tuesday, February 9, 2010 at 1:00 p.m. Eastern ... . , A live audio webcast of the corporate overview will be ...
Cached Medicine Technology:Novus Scientific Receives FDA Clearance for TIGR(TM) Matrix Surgical Mesh - World's 1st Long-Term Resorbable Synthetic Mesh 2Novus Scientific Receives FDA Clearance for TIGR(TM) Matrix Surgical Mesh - World's 1st Long-Term Resorbable Synthetic Mesh 3Poniard Pharmaceuticals to Present at 12th Annual BIO CEO and Investor Conference 2
(Date:5/4/2015)... 05, 2015 The National ... Irene Taylor , Volunteer Executive Director of National ... inductee into its VIP Woman of the Year ... for leadership in business. NAPW is the nation's ... more than 700,000 members and over 200 Local ...
(Date:5/4/2015)... The National Association of Professional Women ... a 2015-2016 inductee into the NAPW VIP Woman of ... distinction for leadership in healthcare. NAPW is the nation's ... than 700,000 members and over 200 operating Local Chapters. ... group of professional women,” says NAPW President Star Jones. ...
(Date:5/4/2015)... (PRWEB) May 05, 2015 The ... Shirley Weis as a 2015-2016 inductee into its ... with this prestigious distinction for leadership in healthcare. NAPW ... women, boasting more than 700,000 members and over 200 ... with this important honor,” says NAPW President Star Jones. ...
(Date:5/4/2015)... IOWA (PRWEB) May 04, 2015 The ... appointed Gregs G. Thomopulos, P.E., Chairman of Stanley ... (ISI) board of directors for a three-year term. ... Association (APWA) and the American Society of Civil Engineers ... a sustainability rating system for civil infrastructure called Envision. ...
(Date:5/4/2015)... 04, 2015 HHT is a rare ... While it can have seemingly mild symptoms like ... events. Hereditary Hemorrhagic Telangiectasia (HHT) is a hereditary ... lack normal capillary connections between an artery and a ... severe nosebleeds, but may also be present in the ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Irene Taylor into its 2015-2016 VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Jennifer Yates Doherty, Owner of Palmetto Rehabilitation Services, LLC, into its 2015 VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Shirley Weis, President at Weis Associates, LLC, into its 2015-2016 VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Shirley Weis, President at Weis Associates, LLC, into its 2015-2016 VIP Woman of the Year Circle 3Health News:Thomopulos Appointed to Institute for Sustainable Infrastructure Board 2Health News:Frequent Nosebleeds Can Be a Sign of a Rare Undiagnosed Disease - Cure HHT 2Health News:Frequent Nosebleeds Can Be a Sign of a Rare Undiagnosed Disease - Cure HHT 3
... May 20 (ZealousPR) Award-winning Vanity,Fair writer and hospice ... tri-weekly "advice column on dying well,", http://www.TheCheckoutLine.org -- ... who care about them, today. Every Monday, Wednesday and,Friday, ... questions,and offering advice for anyone needing help on the ...
... of developing asthma and allergy because of different conditions ... from the Isle of Wight in the United Kingdom, ... 2008 International Conference in Toronto on Wednesday, May 21., ... asthma and allergy in first-born children is the result ...
... Allows Patients the Ability to Share their Prescription ... Longs Drug,Stores Corporation (NYSE: LDG ) announced ... a platform for sharing of information between,patients and ... of the first,pharmacies to provide their customers with ...
... CHICAGO (May 19, 2008) New research published in ... long-term survival and liver rejection rates are equivalent for ... other races. The study also suggests that although other ... influence long-term survival, race does not. , ...
... ... Leadership, CHICAGO, May 19 Ventas, Inc. (NYSE: VTR ... declared,a regular quarterly dividend of $0.5125 per share, payable in cash ... The dividend is the,second quarterly installment of the Company,s 2008 annual ...
... procedure performed by Dr. Robert S. Bray, Jr. of ... D.I.S.C. Spine ... Roach is living,her dream after successfully qualifying for the 2008 ... one of the country,s preeminent,neurological spinal surgeons specializing in micro ...
Cached Medicine News:Health News:Award Winning Vanity Fair Contributing Editor Judy Bachrach Launches 'TheCheckoutLine.org - An Advice Column on Dying Well' 2Health News:First-born babies' higher asthma and allergy rates due to pregnancy conditions 2Health News:Longs Drugs Partners With Google on the Launch of Google Health 2Health News:Study concludes no racial disparities in long-term outcomes in recipients of liver transplants 2Health News:Ventas Declares Regular Quarterly Dividend of $0.5125 Per Share 2Health News:Ventas Declares Regular Quarterly Dividend of $0.5125 Per Share 3Health News:Ventas Declares Regular Quarterly Dividend of $0.5125 Per Share 4Health News:Ventas Declares Regular Quarterly Dividend of $0.5125 Per Share 5Health News:Successful Back Surgery Propels Olympic Weightlifting Hopeful Melanie Roach to Realize Her Dreams Of Participating in the 2008 Beijing Olympics 2
Universal Hub with Varying Blade Edge Diameters For Mounting the Blade to the Handle; Stainless Steel....
2 Sided Pivoted Closed Ring Design,Pointed And Smooth Sides; in stainless steel....
Blunt Tapered Tip in stainless steel....
... meet the high-quality and ... practices. The optional Profile ... accessory features a unique ... increases the accuracy of ...
Medicine Products: